Mu-Tzu Chu

Ms. Mu-Tzu Chu

Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2023 in Biomedicines
Verified
Journal Article
Open access
MCMu-Tzu Chu
Mu-Tzu Chu
WCWan-Chun Chang
Wan-Chun Chang
Shih-cheng PaoShih-cheng Pao
Shih-cheng Pao
Shuen-Iu HungShuen-Iu Hung
Shuen-Iu Hung
Drug hypersensitivity reactions are classified into immediate and delayed types, according to the onset time. In contrast to the immediate type, delayed drug hypersensitivity mainly involves T lymphocyte recognition of the drug antigens and cell activation. The clinical presentations of such hypersensitivity are various and range from mild reactions (e.g., maculopapular exanthema (MPE) and fixed drug eruption (FDE)), to drug-induced liver injury (DILI) and severe cutaneous adverse reactions (SCARs) (e.g., Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP)). The common culprits of delayed drug hypersensitivity include anti-epileptics, antibiotics, anti-gout agents, anti-viral drugs, etc. Delayed drug hypersensitivity is proposed to be initiated by different models of molecular recognition, composed of drug/metabolite antigen and endogenous peptide, HLA presentation, and T cell receptor (TCR) interaction. Increasing the genetic variants of HLA loci and drug metabolic enzymes has been identified to be responsible for delayed drug hypersensitivity. Furthermore, preferential TCR clonotypes, and the activation of cytotoxic proteins/cytokines/chemokines, are also involved in the pathogenesis of delayed drug hypersensitivity. This review provides a summary of the current understanding of the molecular recognition, genetic susceptibility, and immune mediators of delayed drug hypersensitivity.

15 April 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Shih-cheng PaoShih-cheng Pao
Shih-cheng Pao
MCMu-Tzu Chu
Mu-Tzu Chu
Shuen-Iu HungShuen-Iu Hung
Shuen-Iu Hung
Cancer immunotherapy has achieved multiple clinical benefits and has become an indispensable component of cancer treatment. Targeting tumor-specific antigens, also known as neoantigens, plays a crucial role in cancer immunotherapy. T cells of adaptive immunity that recognize neoantigens, but do not induce unwanted off-target effects, have demonstrated high efficacy and low side effects in cancer immunotherapy. Tumor neoantigens derived from accumulated genetic instability can be characterized using emerging technologies, such as high-throughput sequencing, bioinformatics, predictive algorithms, mass-spectrometry analyses, and immunogenicity validation. Neoepitopes with a higher affinity for major histocompatibility complexes can be identified and further applied to the field of cancer vaccines. Therapeutic vaccines composed of tumor lysates or cells and DNA, mRNA, or peptides of neoantigens have revoked adaptive immunity to kill cancer cells in clinical trials. Broad clinical applicability of these therapeutic cancer vaccines has emerged. In this review, we discuss recent progress in neoantigen identification and applications for cancer vaccines and the results of ongoing trials.

1 June 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MCMu-Tzu Chu
Mu-Tzu Chu
Chuang-Wei WangChuang-Wei Wang
Chuang-Wei Wang
WCWan-Chun Chang
Wan-Chun Chang
CCChun-Bing Chen
Chun-Bing Chen
WCWenHung Chung
WenHung Chung
Shuen-Iu HungShuen-Iu Hung
Shuen-Iu Hung